Literature DB >> 26314667

How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.

David Y Graham1, Sun-Young Lee2.   

Abstract

Bismuth triple therapy was the first effective Helicobacter pylori eradication therapy. The addition of a proton pump inhibitor helped overcome metronidazole resistance. Its primary indication is penicillin allergy or when clarithromycin and metronidazole resistance are both common. Resistance to the primary first-line therapy have centered on complexity and difficulties with compliance. Understanding regional differences in effectiveness remains unexplained because of the lack of studies including susceptibility testing and adherence data. We discuss regimen variations including substitutions of doxycycline, amoxicillin, and twice a day therapy and provide suggestions regarding what is needed to rationally and effectively use bismuth quadruple therapy. Published by Elsevier Inc.

Entities:  

Keywords:  Adherence; Bismuth; Helicobacter pylori; Metronidazole; Proton pump inhibitors; Side effects; Tetracycline; Therapy

Mesh:

Substances:

Year:  2015        PMID: 26314667      PMCID: PMC4555994          DOI: 10.1016/j.gtc.2015.05.003

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  107 in total

1.  Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.

Authors:  E Gené; X Calvet; R Azagra; J P Gisbert
Journal:  Aliment Pharmacol Ther       Date:  2003-05-01       Impact factor: 8.171

Review 2.  Evidence-based recommendations for successful Helicobacter pylori treatment.

Authors:  Jeng-Yih Wu; Jyh-Ming Liou; David Y Graham
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-12-02       Impact factor: 3.869

3.  Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection.

Authors:  D Y Graham; J Hoffman; H M el-Zimaity; D P Graham; M Osato
Journal:  Aliment Pharmacol Ther       Date:  1997-10       Impact factor: 8.171

4.  A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study.

Authors:  Antonio Francesco Ciccaglione; Luigina Cellini; Laurino Grossi; Lamberto Manzoli; Leonardo Marzio
Journal:  Helicobacter       Date:  2015-03-20       Impact factor: 5.753

5.  Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.

Authors:  Mehmet Demir; Savaş Göktürk; Nevin Akçaer Oztürk; Ender Serin; Uğur Yilmaz
Journal:  Digestion       Date:  2010-03-05       Impact factor: 3.216

6.  [Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection].

Authors:  Sung Chul Park; Hoon Jai Chun; Sung Woo Jung; Bora Keum; Woo Sik Han; Rok Son Choung; Yong Sik Kim; Yoon Tae Jeen; Hong Sik Lee; Soon Ho Um; Sang Woo Lee; Jai Hyun Choi; Chang Duck Kim; Ho Sang Ryu; Jin Hai Hyun
Journal:  Korean J Gastroenterol       Date:  2004-09

7.  Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.

Authors:  D Y Graham; G Belson; S Abudayyeh; M S Osato; M P Dore; H M T El-Zimaity
Journal:  Dig Liver Dis       Date:  2004-06       Impact factor: 4.088

Review 8.  Bismuth subsalicylate in the treatment and prevention of diarrheal disease.

Authors:  H L DuPont
Journal:  Drug Intell Clin Pharm       Date:  1987-09

9.  Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment.

Authors:  Yildiran Songür; Altuğ Senol; Ayşe Balkarli; Abdülkadir Baştürk; Süreyya Cerçi
Journal:  Am J Med Sci       Date:  2009-07       Impact factor: 2.378

10.  Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.

Authors:  David Y Graham; Yi-Chia Lee; Ming-Shiang Wu
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-08       Impact factor: 11.382

View more
  31 in total

1.  It is time to rethink H. pylori therapy.

Authors:  Bich N Dang; David Y Graham
Journal:  J Gastrointestin Liver Dis       Date:  2017-06       Impact factor: 2.008

2.  Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection.

Authors:  Chang Seok Bang; Hyun Lim; Hae Min Jeong; Woon Geon Shin; Jae Ho Choi; Jae Seung Soh; Ho Suk Kang; Young Joo Yang; Ji Taek Hong; Suk Pyo Shin; Ki Tae Suk; Jae Jun Lee; Gwang Ho Baik; Dong Joon Kim
Journal:  Gut Microbes       Date:  2020-05-02

3.  A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.

Authors:  Feng-Woei Tsay; Deng-Chyang Wu; Hsien-Chung Yu; Sung-Shuo Kao; Kung-Hung Lin; Jin-Shiung Cheng; Huay-Min Wang; Wen-Chi Chen; Wei-Chih Sun; Kuo-Wang Tsai; Ping-I Hsu
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI.

Authors:  David Y Graham; Hong Lu; Maria Pina Dore
Journal:  Helicobacter       Date:  2018-11-15       Impact factor: 5.753

5.  Empiric H. pylori therapy-10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best.

Authors:  Yoshio Yamaoka; David Y Graham
Journal:  Transl Cancer Res       Date:  2016-12       Impact factor: 1.241

Review 6.  Treating Helicobacter pylori effectively while minimizing misuse of antibiotics.

Authors:  Akiko Shiotani; Hong Lu; Maria Pina Dore; David Y Graham
Journal:  Cleve Clin J Med       Date:  2017-04       Impact factor: 2.321

Review 7.  Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy.

Authors:  David Y Graham; Theodore Rokkas; Ruben Hernaez
Journal:  Gut       Date:  2021-11-08       Impact factor: 23.059

8.  Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.

Authors:  Qi Chen; Wei Zhang; Qingyan Fu; Xiao Liang; Wenzhong Liu; Shudong Xiao; Hong Lu
Journal:  Am J Gastroenterol       Date:  2016-09-27       Impact factor: 10.864

Review 9.  Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.

Authors:  David Y Graham; Maria Pina Dore; Hong Lu
Journal:  Expert Rev Anti Infect Ther       Date:  2018-08-23       Impact factor: 5.091

Review 10.  Helicobacter pylori therapy: a paradigm shift.

Authors:  David Y Graham; Maria Pina Dore
Journal:  Expert Rev Anti Infect Ther       Date:  2016-05-03       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.